Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Ali Farahanchi United States

Life Science and Healthcare Venture Capital Investor
Website:
www.dh.vc
Company Size (Fulltime employees)
1-10
Year of foundation
2013
Partnering Objectives
Please specify your partnering goal
Investment
Headquartner in China
No
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
DHVC
Managing Director 
Functionality
Investment

Feida Feida United States

Medical Device Company
Website:
https://www.medtronic.com/us-en/index.html
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
Learn more about medical device market and industry in China
Headquartner in China
No
Medtech Category
Medtronic
R&D engineer 
Functionality
Research and Development

Dr. Crist Frangakis United States

Achelios Therapeutics, Inc., based in RTP Carolina, is a privately held specialty biopharmaceutical company whose core competency is the reformulation of non-steroidal anti-inflammatory drug (NSAID) molecules that have historically been used to treat pain and inflammation by topical application.
Our proprietary formulation allows for fast and enhanced delivery of active agents across human skin into subdermal tissues.
Achelios is currently developing:
OTC 1% diclofenac topical formulation for the treatment of pain and inflammation. Our product shows improved efficacy, better compliance, photoprotection, and dossing schedule vs. Voltaren® ANDA to be submitted in 4Q 2021.
The next product in development is a superior 3% diclofenac formulation being developed for the prescription market for acute and chronic pain. These product has demonstrated greater efficacy, safety and photostability vs. other topical gels available globally. Our product has also shown efficacy as an opioid-spearing agent in the treatment of pain.
Website:
Achelios.com
Company Size (Fulltime employees)
1-10
Year of foundation
2012
Partnering Objectives
Please specify your partnering goal
1. License OTC and RX product ex -US , Asia and EU
Headquartner in China
No
Biotech/Pharma Category
Assets Information 1
OTC1% diclofenac|Topical NSAID|pain and inflamation|global
Assets Information 2
Prescription 3% Diclofenac|Topical NSAID|Acute and chronic pain, opioid spearing|global
Assets Information 3
5%& 3% Ketoprofen topical|Topical Ketoprofen gel|Migraine, TMJD , Chronic pain|global
Biotech/Pharma Asset Stage
Achelios Therapeutics
President & ceo 
Functionality
Management

Dr. Shao Fu United States

A specialty company located in NJ focusing developing 505b2s and complex generics
Website:
Www.nvspharm.com
Company Size (Fulltime employees)
11-50
Partnering Objectives
Please specify your partnering goal
Project codevelolment
Headquartner in China
No
Novelstar Pharmaceuticals Inc.
VP 

TED FUNG United States

Golden State Green World LLC, is a CBG Hemp Cultivator, located in Riverside County, California. Our team has ten years of extensive greenhouse design and a diverse growing experience. We apply our grow methodologies and eco-agricultural knowledge to supply the global market with high quality, contaminant-free, organic CBG enriched hemp products. Our vision is to become a global distributor of organic CBG infused products that will provided medical and therapeutically benefits to the end user.
Website:
www.gsgreenworld.com
Company Size (Fulltime employees)
10-Jan
Year of foundation
2014
Partnering Objectives
Headquartner in China
No
Golden State Green World
International Sales Manager 
Functionality
Sales and Marketing

Dr. Ivana Gelineo-Albersheim United States

Swissaustral is a worldwide specialist in Extreme Biotechnology developing innovative solutions for non-standard technological challenges in Life Sciences and different areas of Industry. Our company exploits the potential of extremophilic microorganisms and their unexplored metabolic pathways as a unique and diverse natural source for biocompounds of various industrial applications going from pharmaceutical, chemical, food and biotechnology.
Website:
www.swissaustral.com
Company Size (Fulltime employees)
11-50
Year of foundation
2006
Partnering Objectives
Please specify your partnering goal
To find companies in China interested in distributing and commercialize our products and services
Headquartner in China
No
Your Research Tool and Service name
Extremophilic enzymes, other biocompounds endotoxin free of high purity
Service Description
We offer some highly stable enzymes for different applications. Our endotoxin free enzymes could be used in pharma developments. We provide services discovering new enzymes and other biocompounds of high stability.
Target client type
Pharma and biotech companies
Swissaustral
Business Development Director 
Functionality
Business Development

Chad Gloetzner United States

MedSci Healthcare was established in 2002 with the creation of Bioon.com, with headquarters in Shanghai and internationally in the U.S. We are committed to be the bridge between China and the U.S. healthcare. This is done by connecting Chinese healthcare professionals (HCPs) with U.S. resources and vice versa.
The company has done projects with major companies such as: Pfizer, Harvard Medical School, AstraZeneca, GSK, Abbott, Johnson & Johnson, Takeda, Novartis, Medtronic and many more. We have also worked with organizations such as the China Cardiovascular Association (CCA), Chinese Medical Doctor Association (CMDA) and more.
MedSci is a digital academic platform, scientific publishing support and multichannel marketing (MCM) organization. We use the term Academic Promotion Organization (APO). We use scientific writers, doctors & researcher scientists and commercialization experts to develop customized strategy & implementation to reach each organization’s goals.
Website:
medsci.cn
Company Size (Fulltime employees)
201-500
Partnering Objectives
Please specify your partnering goal
Looking for mutually beneficial partnerships and clients.
Headquartner in China
No
Biotech/Pharma Category
MedSci Healthcare
VP of Sales and Operations 
Functionality
Management

Mrs. Loren Gordon United States

It is a University
Website:
uh.edu
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
I am a part of an organization of medical students
Headquartner in China
No
Biotech/Pharma Category
University of Houston
student 
Functionality
Business Development

Mr John Gregg United States

BalinBac Therapeutics, Inc. is a clinical stage biopharmaceutical development company headquartered in Princeton, New Jersey, focused on rapidly bringing both repurposed and new antivirals and antibiotics to market. BalinBac started working on coronavirus drug solutions in January 2020 when the team predicted the impact of the COVID-19 pandemic.

Our scientists and therapeutics development executives have a wealth of working knowledge in the pharmaceutical industry and have a track record of successfully bringing key antiviral and antibacterial drugs to market. We know how to rapidly get drugs to patients and what it takes to get this work done quickly.
Website:
www.balinbac.com
Year of foundation
2014
Partnering Objectives
Headquartner in China
No
Assets Information 1
BalinBac has a lead clinical stage drug (phase 2/3) repurposed candidate, BB-708, with validated COVID-19 suppressing antiviral activity utilizing multiple recognized mechanisms of action. This SARS-CoV-2 activity has been demonstrated in a number of labs at a drugable micromolar level in human lung cell NHBE and Calu-3 cell line viral neutralization assays. BB-708 is a drug product in a unique inhaled drug delivery system that will stop viral replication of SARS-CoV-2. BalinBac’s multiple MOA anti-coronavirus drugs and inhaled delivery system provides a platform for repurposed therapeutics that will now have 20-year composition of matter patents as NCEs through BalinBac’s proprietary medicinal chemistry. This platform will be extended to other therapeutic areas after addressing the huge unmet need of the COVID-19 pandemic. We are seeking research collaboration and option agreements with big pharma and generic companies and are raising super-angel money to finance some small contributing studies relating to the formulation and for some general operating administrative expenses. We will be delivering the drugs to outpatients via electronic cigarettes in free base form and after this program enters the clinic will be developing a new device for hospital inpatient administration. We would be happy to talk to you about collaboration agreements and early investment.
Biotech/Pharma Asset Stage
Mr John Gregg
BALINBAC THERAPEUTICS, INC.
CEO 
Functionality
Management

Henry Han United States

EpicentRx is an immuno-oncology company whose focus is to identify and develop less toxic and more effective immunotherapy-based anti-cancer treatments that are active not only as single agents, but that also sensitize tumors to the cytotoxic effects of chemotherapy, radiation and immune checkpoint blockade. EpicentRx's lead program is among a portfolio of novel dinitroazetidine-based drugs that downregulate CD47 – SIRPα to alter the tumor microenvironment and optimize immune responses as well as normalize the tumor vasculature for better drug and oxygen delivery, and has been tested in several clinical trials including an ongoing Phase 3 study in SCLC. The company is also advancing multiple programs through its smart virus AdAPT platform, including three anti-SARS-CoV-2 vaccines, a TGF-beta "trap" starting Phase 1, and various personalized cancer vaccines that have shown to be effective in both chemotherapy and immune resistant tumors. For more information regarding EpicentRx, go to: http://www.epicentrx.com.

Website:
https://www.epicentrx.com
Partnering Objectives
Biotech/Pharma Category
Biotech/Pharma Asset Stage
EpicentRx
BD Head 
Functionality
Business Development